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Abstract
Background: Epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSC) contribute to tumour
progression and metastasis. Assessment of transcription factors involved in these two mechanisms can help to
identify new targets for an oncological therapy. In this study, we focused on the evaluation of the transcription
factor Six1 (Sine oculis 1). This protein is involved in embryologic development and its contribution to
carcinogenesis has been described in several studies.
Methods: Immunohistochemistry against Six1 was performed on a tissue microarray containing specimens of
primary pancreatic ductal adenocarcinomas (PDAC) of 139 patients. Nuclear and cytoplasmic expression was
evaluated and correlated to histopathological parameters. Expression of Six1 was inhibited transiently by siRNA in
Panc1 and BxPc3 cells and stably by shRNA in Panc1 cells. Expression analysis of CDH1 and Vimentin mRNA was
performed and cell motility was tested in a migration assay. Panc1 cells transfected with Six1 shRNA or scrambled
shRNA were injected subcutaneously into nude mice. Tumour growth was observed for four weeks. Afterwards,
tumours were stained against Six1, CD24 and CD44.
Results: Six1 was overexpressed in the cytoplasm and cellular nuclei in malignant tissues (p < 0.0001). No
correlation to histopathological parameters could be detected. Six1 down-regulation decreased pancreatic cancer
cell motility in vitro. CDH1 and vimentin expression was decreased after inhibition of the expression of Six1.
Pancreatic tumours with impaired expression of Six1 showed significantly delayed growth and displayed loss of the
CD24+/CD44+ phenotype.
Conclusion: We show that Six1 is overexpressed in human PDAC and that its inhibition results in a decreased
tumour progression in vitro and in vivo. Therefore, targeting Six1 might be a novel therapeutic approach in patients
with pancreatic cancer.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is a highly ma-
lignant tumour with a poor prognosis. Despite its low
prevalence, it is the fourth leading cause of cancer-related
death in western countries [1]. Pancreatic cancer spreads
rapidly and is highly resistant to chemotherapy. These fea-
tures are determined by several biological features, which
are considered to be hallmarks of tumour development
and dissemination [2]. Among those fundamental corner-
stones, epithelial-to-mesenchymal transition (EMT) plays
a crucial role in tumour progression. By adopting a more
mesenchymal phenotype, cells increase motility, augment
invasiveness und enhance chemoresistance [3]. EMT is
strongly connected to the concept of cancer stem cells
(CSC) [4]. In this model, CSC represent only a minor frac-
tion of a tumour but are hypothesized to be crucially
involved in its progression [5]. They can divide infinitely
and are strongly resistant to chemotherapeutics. There-
fore, they can survive chemotherapy and form recurrent
disease [2]. Brabletz et al. described a model, in which
migrating CSC are responsible for tumour dissemination
whereas the epithelial non-CSC form is responsible for
the growth of a single tumour [4]. In good accordance
with this assumption, Martin et al. showed that EMT
augments self-renewal capability [6].
In this study we focused on the embryologic transcrip-
tion factor Six1 (Sine Oculis 1). It contributes to organo-
genesis by inducing proliferation, migration and survival
[7–9]. In tumour biology, however, Six1 exerts pro-
tumourigenic functions by regulating EMT-related
mechanisms [10]. The role of Six1 in carcinogenesis has
already been studied in several malignancies including
breast cancer [11, 12], cervical cancer [13, 14] ovarian
cancer and hepatocellular cancer [15, 16]. Recently, our
group has shown that overexpression of SIX1 is an inde-
pendent prognostic marker in stage I - III colorectal
cancer [17]. Moreover, Li et al. [18] and Jin et al. showed
an overexpression of Six1 in PDAC in their recent stud-
ies. In the study by Jin et al. Six1 was also an independ-
ent prognostic marker in pancreatic cancer [19].
Additionally, Ono et al. showed that Six1 promotes
EMT by activating ZEB1 [20]. The purpose of the
present study was to evaluate the impact of Six1 expres-
sion on CSC- and EMT-phenotypes in PDAC. To this
end, we analysed a tissue microarray including 139
patients. Furthermore, we assessed the impact of Six1 on
EMT markers and migration in vitro in Panc1 and
BxPc3 cells. Finally, we investigated the impact of Six1
on tumour growth in vivo in a xenograft model.
Methods
Patients
The Medical Ethical Committees of the University of
Bonn has approved the use of the patient tissue samples
and clinic-pathological information in this study
(Antragsnummer 13–091). Written informed consent
was obtained from each patient prior to this study. The
study cohort included 139 patients who underwent
tumour resection at the University Hospital of Bonn
between 1998 and 2009. The analysis was performed
retrospectively and it was not possible to deduce patient
identity from patient data. Cores derived from cancer
tissue as well as from adjacent non-affected normal
pancreatic parenchyma were analyzed.
Immunohistochemistry
Immunohistochemical staining of human tissue micro-
array samples was performed as described previously [21].
Likewise, immunohistochemical staining on whole tissue
specimens from xenograft samples was conducted. 2 μm
sections of formalin-fixed, paraffin-embedded tumour
specimens were cut and mounted on SUPERFROST®
PLUS microscope slides (Menzel, Germany). After over-
night incubation at 37 °C, samples were dewaxed with xy-
lol, rehydrated in a graded series of ethanol and subjected
to heat-induced antigen retrieval (Dako REAL™ Target Re-
trieval Solution, pH 6.00, DAKO Denmark A/S) in a pres-
sure cooker for 15 min. Nonspecific binding was blocked
using an Avidin/Biotin Blocking Kit (Vector Laboratories,
Inc., Burlingame, CA, USA). After antigen retrieval, slides
were placed in an automated staining machine (DAKO
Automatic Stainer) and incubated with the primary anti-
body for 30 min. Whole tissue specimens from xenografts
specimens were additionally incubated with primary anti-
bodies against CD44 (Rabbit monoclonal, ab151037,
abcam, United Kingdom) and CD24 (Rabbit monoclonal,
ab17982, Abcam, United Kingdom) for 30 min. Incuba-
tion with primary antibodies was followed by the biotinyl-
ated secondary antibody (DAKO REAL™ Biotinylated
Secondary Antibody Anti -Rabbit, part of the DAKO
REAL™ Detection System Peroxidase/AEC, Rabbit/Mouse,
Code K5003, DAKO, Denmark) for 20 min. Afterwards,
endogenous peroxidase was inhibited (DAKO REAL™
Peroxidase blocking solution, DAKO, Denmark) for 5 min
followed by incubation with DAKO REAL™ streptavidin
peroxidase (HRP) solution (part of DAKO REAL™ Detec-
tion System Peroxidase/AEC, Rabbit/Mouse, Code K5003,
DAKO, Denmark) for 20 min. Finally, the specimens were
visualised with DAKO REAL™ AEC/H2O2 Substrate Solu-
tion (part of DAKO REAL™ Detection System Peroxidase/
AEC, Rabbit/Mouse, Code K5003, DAKO, Denmark) and
counterstained with haematoxylin. Two independent re-
searchers (CK and TL) estimated the expression of SIX1
on a blind basis. A multi-head microscope was used and
consensus was reached for each slide. The staining inten-
sity in cytoplasm was classified as absent: 0, weak or inter-
mediate: 1 and strong: 2. For cell nucleus staining, the
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percentage of positive cells was assessed: absent: 0, 0–
25%: 1, 25–50%: 2, 50–75%: 3, > 75%: 4.
Cell lines and transfection
Panc1 and BxPc3 cell lines were purchased from the
American Type Culture Collection (ATCC, Manassas,
VA 20108, USA). Tumour cells were maintained in
RPMI-1640 (Sigma, St. Louis, MO), supplemented with
10% (v/v) fetal calf serum (FCS), 100 U/ml penicillin and
100 μg/ml streptomycin in a humidified atmosphere of
5% CO2 at 37 °C. The anti-Six1 shRNA plasmid (Mis-
sion® shRNA bacterial glycerol stock, SHCLNG-
NM_005982, Sigma, USA) or an empty control vector
(pLKO.1-puro, SHC001, Sigma, USA) were transfected
using calcium phosphate-mediated transfection285 (Pro-
Fection® Mammalian, Cat. No. E1200, Promega,
Germany) according to the manufacturer’s protocol.
Twenty-four hours after transfection, the cells were
passaged 1:15 in appropriate medium containing 1 μg/ml
puromycin for puromycin selection. Transfection effi-
ciency was determined by quantitative RT-PCR (qPCR). A
transient siRNA transfection [22] was performed using
Lipofectamine 2000 [23] (invitrogen, USA) according to
the manufacturer’s specifications. An anti-Six1 siRNA
from Sigma (Additional file 1: Table S1) and a negative
control siRNA (AllStars, Qiagen, Netherlands) were pur-
chased. Per 1200 pmol of siRNA, 30 μl of Lipofectamine
2000 were used for transfection. Afterwards, cells were
incubated for 24 h and transfection efficiency was deter-
mined using quantitative RT-PCR (qPCR).
RNA extraction and quantitative RT-PCR [24, 25]
Total RNA from Panc1 and BxPc3 cells was extracted
with the miRNeasy Mini Kit (Qiagen, Hilden, Germany)
following the manual’s instructions. RNA concentration
was determined by a spectrophotometer (Nano Drop®
1000, Thermo Scientific, Germany) and reversely
transcribed using the miScript Reverse Transcription Kit
(Qiagen, Hilden, Germany). Five nanogram of the
resulting cDNA was further subjected to qPCR (SYBR
Green PCR Kit, Qiagen, Hilden, Germany) in a Roche
Light Cycler™ (Roche Diagnostics GmbH, Mannheim,
Germany). Ready specific primer pairs were purchased
from Qiagen. Samples were normalized to GAPDH RNA
and fold change of expression was calculated according
to the 2-ΔΔct method as previously described [26].
Cell migration assay
The migration assay was performed using 24 well
migration chambers (ThinCerts™, 8 μm pore, Greiner
Bio-One, 1780 Wemmel, Belgium). Panc1 and BxPc3
cells were starved overnight. Subsequently, 20.000 cells
were plated in each migration chamber in 300 μl serum-
free medium. Subsequently, the migration chambers
were placed on 24 well plates containing medium with
10% (v/v) fetal calf serum. After an incubation for 24 h,
Panc1 and BxPc3 cells at the bottom of the migration
chamber were stained with 4′, 6-diamidino-2-phenylin-
dole (DAPI). 20 representative figures of each migration
membrane were taken using a fluorescent microscope
and the number of migrated cells of each assay was
counted. All assays were performed in triplicates.
Xenograft model
The study was approved by the regional authority for Na-
ture, Environment and Consumer protection of the Land
of North Rine-Westphalia (84–02.04.2015.A038). We used
two groups each containing five mice (Athymic Nude
Mouse, Crl:NU(NCr)-Foxn1nu, Charles River, VA, USA).
2.5 × 106 cells were injected in each flank. Tumour growth
and mice weight were assessed weekly for four weeks.
After four weeks, the mice were euthanasized. Tumour
samples were fixed in formalin and embedded in paraffin
for further immunohistochemical analyses.
Statistical analysis
The software package GraphPad Prism, version 6
(GraphPad Software, La Jolla, CA, USA) was used for all
calculations. Pearson’s r test was applied to analyze the
correlation between the expression of Six1 and patho-
logical parameters. Differences in expression of Six1 in
the PDAC cohort, Panc1 and BxPc3 cells, differences in
migration and differences in tumour growth in vivo were
assessed using the Student’s t-test. The p values of all
statistical tests were 2-sided, and p ≤ 0.05 was consid-
ered to indicate a statistically significant result.
Results
Expression of Six1 in pancreatic ductal adenocarcinoma
and its histopathological correlation
Patient characteristics and clinical specimens
Tissue samples from 139 patients suffering from primary
pancreatic cancer were evaluated by IHC, out of these,
sufficient material and data for final analysis were
available in 137 cases. Of those 137 patients the median
age was 66 years (36–85). 74 patients were male, 59
female. The UICC tumour stage at time of tumour re-
section was I in 2 cases, II in 9 cases, III in 123 cases
and IV in 3 cases. 98 patients had positive lymph node
metastasis (pN1), 38 patients were free of lymph node
metastasis (pN0) and in 1 patient lymph node status was
not known. Tumour grading was I in 1 case, II in 59
cases and III in 54 cases. In 23 cases grading could not
be exactly determined. Characteristics of the cohort are
shown in Table 1.
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Expression of Six1 in human pancreatic ductal
adenocarcinoma
We assessed Six1 expression in tissue samples derived
from 139 patients with primary PDAC. In 137 out of
139 patients, cancer tissue could be evaluated and from
105 out of 139 patients, normal pancreatic parenchyma
could be assessed. Evaluation was performed separately
for Six1 expression in cytoplasm and nuclei, respectively
(Fig. 1). 63.5 of the malignant specimens showed an ex-
pression of Six1 in the cytoplasm, whereas only 13.3%
cases of benign tissue were positive for Six1 expression
in the cytoplasm (p < 0.0001). In detail, 50 malignant tu-
mours were negative, 66 PDAC samples showed a weak
expression of Six1 and 21 tumour specimens had a high
expression of Six1. In contrast, 91 specimens represent-
ing benign tissue were negative and only 14 samples dis-
played a weak expression of Six1 (Table 1). A positive
nuclear expression of Six1 was observed in 40.8% (± 4.2)
of cancer cells (0 = 81 cases; 1 = 31 cases; 2 = 17 cases,
3 = 4 cases, 4 = 4 cases). On the contrary, only 11.4% (±
3.1) of benign pancreatic tissue specimens displayed a
positive expression of Six1 in the nucleus (0 = 93 cases;
1 = 10 cases, 2 = 2 cases). Further analysis between the
expression of Six1 (cytoplasm and nucleus) and clinical
and histopathological data revealed no significant
association of those parameters: tumour stage (p = 1.00
and 0.40, respectively), lymph node status (0.29 and
0.48, respectively), tumour grading (0.95 and 0.19,
respectively) (Table 1 and Additional file 1: Table S1).
Inhibition of Six1 impairs cell migration in vitro
Expression of Six1 was inhibited transiently by siRNA in
Panc1 cells and BxPc3 cells. This resulted in a decreased
expression of Six1 mRNA by 86% in Panc1 cells and by
48% in BxPc3 cells in comparison to controls (Fig. 2a,
b). Furthermore, Six1 was stably downregulated in Panc1
cells using shRNA. This resulted in a decreased expres-
sion of Six1 by 64.5% when compared to control with
scramble shRNA (Fig. 2a). Intriguingly, both approaches
lead to a decreased transcription of E-Cadherin mRNA
in siRNA-transfected (− 53.2%, p = 0.005) and shRNA-
transfected (− 85.2%, p < 0.0001) Panc1 cells (Fig. 2c).
Likewise, we observed a decreased expression of CDH1
mRNA in BxPc3 cells, when Six1 siRNA was transfected
(−30%, p = 0.03) (Fig. 2d). Furthermore, we investigated
the expression of vimentin in both cell lines. There was
a slight, but not significant decrease in siRNA-
transfected and shRNA- Panc1 cells (Fig. 2e). However,
BxPC3 transfected with siRNA against Six1 showed a
Table 1 Correlation of Six1 expression in cytoplasm to histopathological parameters
Parameter Six1 expression in malignant tissue Six1 expression in benign tissue
Number No Weak Strong p-value Number No Weak Strong p-value
Total 137 50 (36,5%) 66 (48,2%) 21 (15,3%) 105 91 (86,7%) 14 (13,3%) 0 <0,0001
Age
< Median 68 (49,6%) 26 (34,8%) 31 11 0,844 47 (44,8%) 38 (80,9%) 9 (19,1%) 0 0,253
≥ Median 69 (50,4%) 24 (34,8%) 35 (50,7%) 10 (14,5%) 58 (55,2%) 53 (91, 4%) 5 (8,6%) 0
Sexa 0,591 0,902
Male 74 (56,5%) 27 (36,5%) 32 (43, 2%) 15 (20,3%) 56 (53,3%) 49 (87,5%) (12,5%) 0
Female 57 (43,5%) 19 (33,3%) 32 (56,01%) 6 (10,5%) 45 (46,7%) 39 (85,7%) 6 (14,3%) 0
Tumor sizeb 1,000 0,428
pT1 2 (1,5%) 1 (50,0%) 1 (50,0%) 0 2 (1,9%) 2 (100%) 0 0
pT2 9 (6,7%) 3 (33,3%) 5 (55,5%) 1 (11,1%) 8 (7,6%) 7 (87,5%) 1 (12,5%) 0
pT3 121 (89,6%) 42 (34,7%) 59 (48,8%) 20 (16,5%) 90 (85,7%) 79 (87,8%) 11 (12,2%) 0
pT4 3 (2,2%) 2 (66,7%) 1 (33,3%) 0 3 (2,9%) 3 (100%) 0 0
Lymph node metastasisc 0,290 0,959
N0 38 (27,9%) 4 (10,5%) 19 (50,0%) 15 (39,5%) 31 (29,5%) 28 (90,3%) 3 (9,7%) 0
N1 98 (72,1%) 34 (34,7%) 47 (48,0%) 17 (17,3%) 74 (70,5%) 63 (85,1%) 11 (14,9%) 0
Grading 0,950 0,715
G1 1 (0,7%) 0 1 (100,0%) 0 1 (1,0%) 1 (100%) 0 0
G2 59 (43,1%) 21 (35,6%) 28 (47,5%) 10 (16,9%) 44 (41,9%) 38 (86,4%) 6 (13,6%) 0
G3 54 (39,4%) 18 (33,3%) 28 (51,2%) 8 (14,8%) 45 (42,9%) 38 (84,4%) 7 (15,6%) 0
Gx 23 (14,4%) 11 (47,8%) 9 (39,1%) 3 (13,0%) 15 (14,3%) 14 (93,3%) 1 (6,7%) 0
asex was known in 131 malignant and 101 benign specimens. bTumor size was known 135 malignant and 103 benign specimens. cLymph node metastasis was
only known in 136 malignant specimens
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significantly declined expression of vimentin by 58.6%
(p = 0.04) (Fig. 2f ).
To assess the impact of Six1 inhibition on cell motility,
we performed migration assays with Panc1 and BxPc3
cells, which had been transfected with siRNA against
Six1 or control. Inhibition of Six1 reduced migration in
Panc1 cells by 37% (p = 0.008) and in BxPc3 cells by
24.2% (p = 0.031) (Fig. 2g, h, Additional file 2: Fig. S1).
Effects of Six1 down regulation in Panc1 cells in vivo
We assessed the effect of Six1 inhibition in Panc1 cells in
vivo in a xenograft model. For this analysis, shRNA-
transfected Panc1 cells were used, showing a stably de-
creased expression of Six1. After injection of tumour cells
into nude mice (2.5 × 106 cells/mouse), body weight and
tumour growth were observed for four weeks (Fig. 3a–c).
The body weight did not show any difference between these
two groups during the observation time. In the beginning,
the average tumour volume was 47.65 mm3 (±19.34) in the
control group (Panc1shctrl) and 47.00 mm3 (±15.90) in the
group with Six1-shRNA (Panc1shSix1). After two weeks, the
tumour volume had increased to 86.78 mm3 (±33.93) in the
control group and had declined to 39.84 mm3 (±18.54) in
Panc1shSix1group (p = 0.0018). At time of euthanasia, the
average tumour volume was 124.13 mm3 (±46.59) in the
Panc1shctrl group and 50.22 mm3 (±29.76) in Panc1shSix1 (p =
0.0008). After euthanasia, tumour samples of both groups
were immunostained against Six1. As expected, tumours
from the Panc1shctrl group showed a higher expression of
Six1 than tumours from the Panc1shSix1 group (Fig. 3d).
Interestingly, in the tumour specimens of the Panc1shctrl
group, we observed an increased expression of Six1 at the in-
vasive edge where EMT plays an important role for tumour
invasion. Moreover, we evaluated the expression of CD44
and CD24 in those murine tumour samples to assess the
co-expression of EMT markers and surrogate markers
associated with a CSC phenotype [27]. Four out of five
control tumours were CD44+/CD24+ whereas all Six1-
downregulated tumours lost that phenotype and were CD44
−/CD24+ (Fig. 3d, e, and f and Additional file 3: Table S2).
Discussion
Pancreatic cancer (PDAC) is one of the most aggressive
types of tumours. For the last decade, its tumour biology
Fig. 1 Six1-Expression in the patient cohort. Staining against Six1 was performed and Six1 expression was determined in cytoplasm and cell
nucleus on a tissue microarray including human samples of patients with pancreatic cancer. a Negative Six1 expression in cytoplasm and nucleus
b Negative Six1 expression in cytoplasm and positive nucleus staining c Weak Six1 expression in cytoplasm without nucleus staining. d Weak Six1
expression in cytoplasm and positive nucleus staining. e Strong Six1 expression in cytoplasm and negative nucleus staining. Annotations above
the panel rows indicate the magnification scale of the figures: first and third row: 40× magnification. Second and fourth row: 100× magnification












Fig. 2 Expression of Six1, CDH1 and vimentin in Panc1 and BxPc3 cells. a Six1 inhibition by shRNA or siRNA decreases Six1 expression in Panc1
cells in comparison to control (scramble shRNA or siRNA). b Six1 inhibition siRNA decreases Six1 expression in BxPc3 cells in comparison to
scramble siRNA. (C) CDH1 expression in Panc1 cells is reduced after Six1 downregulation. d CDH1 expression in BcPc3 is decreased after Six1
downregulation. e Vimentin expression in Panc1 cells is not altered by Six1 downregulation. f Vimentin expression in BxPc3 cells is decreased by
downregulation of Six1. g Downregulation of Six1 impairs migration of Panc1 cells. h Downregulation of Six1 impairs migration of BxPc3 cells
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has been more and more elucidated, revealing the im-
portant role of EMT in tumour progression. Therefore,
in this study, we focused on Six1, which originally has
been described as an EMT regulator under physiological
conditions in numerous types of tissue. However, its role
in carcinogenesis has also become more evident recently
[11, 12, 17]. In PDAC, two studies have investigated the
role of Six1 so far [18, 19]. They demonstrated that over-
expression of Six1 is associated with tumour stage,
lymph node status and grading. Furthermore, Li et al.
[18] showed that increased expression of Six1 is an inde-
pendent prognostic marker for survival in pancreatic
cancer. Our cohort consisted of 139 patients suffering
from primary PDAC who were operated on at the uni-
versity hospital in Bonn between 1998 and 2009. To our
knowledge, this is the largest cohort of patients with
PDAC in which the expression of Six1 has been investi-
gated to date. In 137 malignant and 105 benign samples,
Six1 expression was assessed. In accordance with the
two previous studies, we observed an overexpression of
Six1 in cancer cells compared to healthy tissue. In con-
trast, we did not find a significant correlation between
the expression of Six1 and any clinical or histopatho-
logical data. These controversial observations may be
explained by the different clinical characteristics of our
cohort in comparison to the previous studies: in our
analysis, almost all tumours were diagnosed as stage
pT3, grading G2 or G3 and lymph node status pN1. On
the contrary, the population of Jin et al. was more
heterogenous and tumours were in a less advanced
stage. Taking into account the very homogenous charac-
teristics of our cohort, statistical analysis would require
Fig. 3 Six1 downregulation results in a growth arrest of Panc1 cells in a xenograft model. a Body weight curve of mice. Straight line: Panc-1 tumours
with scramble shRNA (Panc1shCtl). Dashed line: Panc-1 tumours with Six1-shRNA (Panc1shSix1). No difference in body weight in both groups. b Tumour
growth curve of Panc-1 tumours. Straight line: Panc-1 tumours with scramble shRNA (Panc1shCtl). Dashed line: Panc-1 tumours with Six1-shRNA
(Panc1shSix1). c Tumour volume of Panc-1 tumour after resection from xenograft models. Upper panel: Panc-1 tumours with Six1-shRNA (Panc1shSix1).
Lower panel: Panc-1 tumours with scramble shRNA (Panc1shCtl). d Representative figures for expression of Six1 in Panc-1 tumours with scramble shRNA
(left panel) and tumours with Six1-shRNA (right panel). e,f Representative figures for expression of CD44 e and CD24 f in Panc-1 tumours with scramble
shRNA (left panel) and tumours with Six1-shRNA (right panel)
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a much higher number of participants to find a signifi-
cant correlation.
EMT has been described as one of the hallmarks of can-
cer [2]. It increases motility and invasiveness. In line with
this hallmark, we demonstrated that decreased expression
of Six1 results in an impaired motility of Panc1 and BxPc3
cells. Several proteins were proposed as surrogate markers
of EMT. CDH1 is a protein involved in cell-cell-contacts,
thereby often used as marker for epithelial character [28].
Vimentin is an intermediate filament used as a surrogate
for mesenchymal differentiation [29]. Under the assump-
tion that Six1 induces a more mesenchymal phenotype,
one would conjecture that Six1 down-regulation results in
an increased expression of CDH1 and a decreased expres-
sion of vimentin. Intriguingly, in our study we were able
to show by several independent experiments that
decreased expression of Six1 induces a declined transcrip-
tion of CDH1 in Panc1 and in BxPc3 cells. Moreover,
reduced expression of Six1 slightly affected the expression
of vimentin in Panc1, but showed a decreased regulation
of Vimentin in BxPc3 cells. To some extent, these data are
diametrically opposed to the assumed results. It is unlikely
that the decreased expression of CDH1 is an arbitrary
result of our transfection method or of the used siRNA.
We performed our experiments in two different cell lines.
Moreover, the expression of Six1 was reduced significantly
by siRNA and by shRNA in comparison to scramble
shRNA or control siRNA, respectively. In the light of this,
our results underscore that both, CDH1 and Vimentin,
are rather surrogate markers for EMT. There exists no
definite and unique EMT marker. Cells undergoing EMT
exhibit rather a dynamic phenotype, where epithelial and
mesenchymal features occur in the same time. This is part
of the EMT-MET (mesenchymal-to-epithelial transition)
axis which regulates the phenotype of a pro-invasive (mes-
enchymal) state and an epithelial phenotype. Both types of
differentiation are important for tumour spread: the mes-
enchymal state is important for tumour invasion whereas
the epithelial state is required for the colonisation and for-
mation of metastasis in distant organs. Such biphasic
effects have also been observed for other EMT-related
transcription factors, such as TWIST1 [30]. This tran-
scription factor can induce the expression of miR-424,
potentially facilitating earlier, but repressing later stages of
metastasis by regulating an EMT-MET axis [30]. It
remains speculative but our data may indicate that inhib-
ition of Six1 may affect the EMT-MET axis by regulating
both mesenchymal and epithelial genes. However, a rela-
tive preponderance of mesenchymal processes versus
epithelial processes may shift the balance towards a pro-
migratory phenotype, which may explain the results of
our migration assays.
Finally, we investigated the impact of Six1 in Panc1
cells in a xenograft model. In this experiment we could
observe that tumour growth was impaired significantly
when the expression of Six1 was decreased in stable
transfected clones by shRNA. These data are in good ac-
cordance with the assumption that the inhibition of
EMT-related transcription factors results in a diminished
tumour growth [31]. To further elucidate those findings,
we evaluated the expression of cancer stem cell (CSC)
markers in the murine xenograft tumours. Ford et al.
have described that Six1 increases the population of
CSCs in breast cancer [32]. Conclusively, we hypothe-
sized that decreased expression of Six1 would also result
in a reduced number of tumour cells with a CSC-
phenotype. We therefore analysed the expression of CD24
and CD44 since Li et al. [27] had identified CD24+/CD44
+/ESA+ cells as pancreatic cancer stem cells. In our experi-
ment, control tumours displayed a significantly stronger
expression CD24+/CD44+ cells than tumours with down-
regulation of Six1. The latter were characterised by cells
with a CD24+/CD44− phenotype, which represents cells
with less CSC features. These findings may suggest that
decreased expression of Six1 impairs fundamental CSC
functions which also results in a less aggressive and less
invasive phenotype. Although this result is in good ac-
cordance with biological hypotheses and findings in breast
cancer, further studies would certainly be warranted to
better characterize the effects of Six1 on CSC induction in
PDAC in vitro and in vivo.
Conclusion
In conclusion, in the largest cohort of patients studied so
far, we confirm the results of previous reports that Six1 is
overexpressed in PDAC. Furthermore, we show that in-
hibition of Six1 leads to decreased cell motility in Panc1
and BxPc3 cells. These results are in good accordance
with the hypothesis that Six1 induces EMT. Interestingly,
CDH1 mRNA expression was also decreased by impaired
expression of Six1 which deserves further investigation in
following studies and may reflect a biphasic effect of Six1
on the EMT-MET axis. Moreover, our data show that
stable inhibition of Six1 decreases tumour growth in a
xenograft model. This is associated with a decreased
expression of CSC-markers in the tumour tissue. Overall,
our results provide further evidence that Six1 co-promotes
tumour progression in pancreatic cancer. Therefore,
targeting Six1 might be a novel promising therapeutic
approach in patients with pancreatic cancer.
Additional files
Additional file 1: Table 1. Six1 expression in the cell nucleus of
malignant and benign tissue and its correlation to clinical and
histopathological parameters. *Only 135 malignant and 103 benign
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